Introduction
Recently, with the development of physiological and biochemical research, a new nuclear orphan receptor (OR) has been the focus of increasing interest and was named an OR because of its unique physiological effect and the inability to identify corresponding specific natural ligands. Moreover, it has characteristics of non-ligand-dependent activation and transcription and interacts with numerous factors and targeted genes through a DNA-binding domain. Giguère et al 1 first reported a family of ORs called estrogen-related receptors (ERRs), which included ERRα, ERRβ, and ERRγ. Among them, the ERRα subtype, which has attracted the greatest attention to date (Figure 1 ), regulates various cellular events, such as energy metabolism and mitochondrial biogenesis where it acts in coordination with its specific transcriptional coactivators, including coactivator-1α (PGC-1α), PGC-1β, peroxisome-proliferator activated receptor γ (PPARγ), 2 steroid receptor coactivators, and corepressor nuclear receptor interacting protein 140 (RIP140). 3 ERRα is considered to control energy homeostasis, 4 by regulating lipid handling, gluconeogenesis, glycolysis, and mitochondrial respiration. Furthermore, metabolic reprogramming is thought to be a characteristic of cancer. [5] [6] [7] [8] [9] [10] Under stress conditions, it can provide tumor cells with an adaptable metabolism and survival mechanisms. [11] [12] [13] Recent studies have reported that the different expression levels of ERRα have important clinical significance in breast, 14 prostate, 15 and colon 16 cancers. Therefore, the ERRα was presumed to be an independent factor for the poor prognosis of hormone-related tumors. 17 Inspired by the successful application of ERs in breast cancer and the discovery that ERRα is involved in regulating 
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Liu et al cellular energy metabolism by controlling targeted genes, increasing interests have been expressed in investigating how this metabolic regulator affects the occurrence and development of carcinoma and in developing clinically useful ERRα antagonists. Furthermore, emerging information on the ERRα has highlighted molecules of its upstream and downstream pathways, which may be inhibited to achieve therapeutic synergism with ERRα antagonists.
eRRα, a master regulator of cellular metabolism in different tissues
Localization analysis in different metabolic tissues such as mouse heart, 18 macrophages, 19 kidney, 20 liver, 21 and human cancer cells 22 have identified numerous genes. These findings might suggest that the ERRα acts as a major regulator of energy metabolism. From the metabolic gene network, there are numerous mitochondrial genes involved in mitochondrial function, such as energy production, amino acid metabolism, nucleotide biosynthesis, etc. ERRα occupies the extended promoter region of genes encoding numerous enzymes involved in such processes as carbohydrate and pyruvic acid metabolism and the tricarboxylic acid cycle (TCA). 23, 24 Furthermore, the ERRα regulon includes all genes encoding enzymes involved in the glycolysis pathway to integrate two main energy-generating pathways under the control of some identical transcription factors (TFs) as well as the promoter regions of genes contributing to lipid metabolism (including acyl-CoA dehydrogenase medium chain [ PubMed (135) GO (29) miRNA ( 
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ERRα regulates cellular metabolism in gynecological endocrine-related cancer Twenty types of metabolism-related genes regulated by ERRα were identified using bioinformatics analysis with the STRING 10.5 database of protein-protein interactions. 25 The data showed that PGC-1α and peroxisomeproliferator activated receptor α (PPARα) were clearly related to ERRα (Figure 2 ). ERRα as a master metabolism regulator was well known to have an important role in maintaining cancer phenotypes by altering cellular bioenergetics 26, 27 Investigating an estrogen signaling-independent function for the ERRα in tumor is arousing increasing interest. In conclusion, the PGC-1α/ERRα axis, as the key point of energy metabolism in malignant tumor cells, is involved in mediating the metabolism through transcription factors. Figure 3 shows the signal pathways and molecular mechanisms of how ERRα affects the bioenergetics of cancer cells, and then changes the behavior of invasion, metastasis and drug resistance of cancer cells based on the bioinformatics analysis.
Through mediating metabolic adaptations, eRRα drives cancer cell growth, division, and proliferation
Metabolic alterations support tumor progression, including rapid growth, proliferation, drug resistance, migration, and metastasis. The metabolic alterations include variations in levels of fatty acid oxidation (FAO) and lipid biosynthesis, increased glutamine uptake and glutaminolysis, elevated flux through the pentose phosphate pathway and aerobic glycolysis, oxidative phosphorylation. 28 The ERRα has been involved in the processes mentioned above through the transcriptional regulation of associated target genes. 24 Recently, many researchers have confirmed the important function of ERRα as well as its corresponding cofactors (in particular, PGC-1s) in the metabolic profiles of tumor cells. 29 Based on the metabolic functions mediated by ERRα, the specific pathway mediating endocrine-related gynecological cancer has been of interest and is still unclear. 
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The biological characteristics of cancer cells include unrestrained cell growth and division. A recent study reported that during glucose deprivation, some breast cancer cells switched to metabolism of lactic acid to provide the essential energy and metabolites for prolonged periods. The switch from glucose to lactate enhances resistance to inhibitors of phosphoinositide 3-kinase (PI3K)/mechanistic target of rapamycin kinase (mTOR) signaling, which is necessary for cancer cell rapid growth and cellular survival. Moreover, ERRα was shown to be crucial for OXPHOS, and the expression of gene-coding enzymes linked to lactate metabolism, such as monocarboxylate transporter 1 (MCT1) and lactate dehydrogenase B (LDHB). Furthermore, inhibition of ERRα by antagonists abrogated lactate metabolism and cellular growth. 30 The division in normal cells is tightly regulated by a series of events. The progress depends mainly on both the cell Figure 3 The potential mechanism of eRRα in energy metabolism: the PGC-1α/eRRα axis, as the key point of energy metabolism in cancer cells, is involved in mediating the metabolism of lipids, glycolysis, and glutamine through transcription factors that affect the bioenergetics of cancer cells, and then changes the behavior of invasion, metastasis and drug resistance of cancer cells. Abbreviations: eRRα, estrogen-related receptor α; PPAR γ, peroxisome-proliferator activated receptor γ; FASN, fatty acid synthase; TCA, tricarboxylic acid cycle; ROS, reactive oxygen species. 
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ERRα regulates cellular metabolism in gynecological endocrine-related cancer cycle and large amounts of energy. 27 The transition to fueling anabolic processes must happen to produce sufficient nucleic acids, lipids and proteins for these events. 27 The expression P21 blocked the G1/S transition after inhibiting ERRα in breast cancer. 31 This ERRα-dependent arrest at the G1/S checkpoint was mirrored. 32 In view of the fact that tumor cells will increase the glycolytic pathway in G1 phase, 33, 34 it may be concluded that ERRα can regulate transition through the cell cycle by controlling cellular energetics. Therefore, Willy et al 35 and Chisamore et al 36 used two synthetic inverse agonists to deactivate ERRα to further study the effects of expression of ERRα on the cell cycle. The results of these two studies revealed that exposure to the two synthetic inverse agonists blocked the growth of breast tumor cell lines and inhibited their tumorigenicity in vivo. The effect of the synthetic inverse agonist, compound XCT790, was accompanied by cell cycle arrest in the G1/S transition as well as production of p21 and hypophosphorylation of retinoblastoma (Rb). 31 Interestingly, in uterine endometrial carcinoma, knockdown of ERRα caused cell cycle blockade at the G2/M phase through cell cycle analysis, whereas it induced cell cycle arrest in the mitotic phase in time-course experiments. 37 Thus, we can conclude that ERRα knockdown caused cell cycle blockade at different phases by energy transition.
The metabolic effects of eRRα promote cancer migration and metastasis A feature of invasive cancers is that their ability to metastasize, which is determined by their invasiveness and migratory ability, as well as tumor angiogenesis that not only provides sufficient oxygen and nutrients but is also a pathway for cells to remove waste. 38 The underlying mechanisms of these effects have not yet been elucidated, but may involve ERRα-driven genes to regulate tumor cell expansion. ERRα synergizes with and increases the transcriptional activities of hypoxia-inducible factor (HIF), 39 which controls glycolytic metabolism 40 and has been associated with the HIFα/β heterodimer in promoting its transcriptional activity on angiogenic and migratory target genes such as VEGF. 41, 42 Further, Semenza 43 has confirmed that ERRα directly interacted with HIF-1α, which controls the transcription involved in angiogenesis and reprogramming energy metabolism, thereby enhancing HIF-1 signaling. 43 HIF-1α expression and the PI3K/Akt/STAT3 (acute phase response factor) signaling pathways are known as key pathways in regulating the expression of VEGF. Thus, we can conclude that VEGF and PI3K/Akt/STAT3 signaling pathways are involved in the ERRα block-mediated anti-angiogenesis in breast tumor cells. 44 Furthermore, ERRα increased the expression of endothelial nitric oxide synthase, to promote angiogenesis. [45] [46] [47] Altogether, ERRα-regulated positive expression of VEGF, which has been reported in breast and cervical tumor, however, pharmacological inhibition of ERRα activity decreased tumor growth and angiogenesis. 39, 48, 49 The propensity of epithelial cancer cells to localize to metastatic sites is primarily dependent on epithelialmesenchymal transition (EMT) in combination with the accumulation of migratory and invasive capacities. Wang et al 50 found that ERRα expression and EMT in ovarian cancer cell lines were inhibited by cordycepin, which downregulated mitochondrial activity, avoiding EMT and migration in vitro. Inhibition of ERRα decreases the metastatic ability by interfering with epithelial-to-mesenchymal gene program suppression. Interestingly, the metabolic enzymes and metabolic profiles are statistically different between proliferating cells and migrating cells undergoing EMT, which exhibit alterations. 51 On the other hand, depletion of fatty acid synthase (FASN) and succinate dehydrogenase induced EMT in ovarian cancer cells, 52 which implied that metabolic alterations have an important role in regulating EMT. In addition, the ERRα can mediate Snail, which is a crucial regulator of EMT. 53 Furthermore, Zhao 54 and Dwyer 55 reported that crosstalk with the Wnt/β-catenin signaling pathway promotes ERRα-mediated cell migration to regulation of WNT11. Inhibiting the expression of ERRα decreases the migratory capacity of cancer cells, as well as ablation of β-catenin, so the ERRα/β-catenin/WNT11 signaling pathway may be biologically significant. Moreover, postgenomics has identified target genes of ERRα, which promoted angiogenesis and were closely related to cellular invasion and migration, such as fibroblast Growth Factor 2 (FGF2) and C-X-C chemokine receptor type 4 (CXCR4). 56 On the other hand, FAO is very important for energy production of cancer cells under some conditions. 57 The transfer of lipids from the microenvironment triggers FAO, which in turn promotes metastasis. 58 In fact, it has been reported that β-oxidation of fatty acids, protein levels of ERRα, and glucose metabolism levels of tumor cells in the brain increases metastases. Metabolic reprogramming driven by ERRα contributes to the variation of these observed metastatic potentials. Cancer cells exhibit different metabolic characteristics at different tumor metastasis sites. Thus, along with the use of energy-producing pathways in cancer cells is altered to promote colonization and survival in specific organs. Experiments in vivo have shown that the oxygenation and nutritional status of the tumor were dynamic. In addition, tumor cells can rapidly ingest and metabolize extremely low levels of glucose, but cancer cells must depend on other sources to gain energy in some conditions. For example, some breast carcinoma cells can use lactic acid as their primary source of energy, allowing them to survive without glucose for long periods. Studies have shown that ERRα regulates the expression of genes required for lactic acid utilization, and it has been shown in isotope analysis experiments that inhibition of ERRα activity inhibits lactate oxidation. 59 In the absence of glucose, lactate oxidative capacity is essential for breast cancer cells, and ERRα antagonists can disrupt mitochondrial function, thereby inhibiting cellular utilization of lactic acid. It has further been demonstrated that most breast cancer cells actively involved in OXPHOS are not sensitive to the inhibition of PI3K/mTOR inhibitors, but the efficacy of these targeted therapies can be enhanced by the combination of ERRα antagonists. 30 ERRα, a major regulator of energy metabolism, was restored in lapatinib-resistant breast tumor cells via the mTOR signaling pathway. Under therapeutic stress circumstance, ERRα reexpression in drug-resistant cells can trigger changes in cellular metabolism, such as increasing in glutamine metabolism and detoxification of reactive oxygen species required for cell survival. ERRα inverse agonist blocked these metabolic changes and relieved lapatinib resistance in a HER2-induced mouse model of breast cancer. This study reveals the molecular mechanism by which ERRα-mediated metabolic reprogramming promotes the survival of lapatinibresistant cancer cells and demonstrates the potential of inhibiting ERRα as an effective adjuvant therapy for HER2-positive but poor outcome breast carcinoma. 60 eRRα plays an important function in endocrine-related gynecological carcinoma Hormones are a very important factor in maintaining the physiological functions of women, and their imbalance is closely associated with the initiation and development of malignant carcinomas. The three most common malignancies in females are breast cancer, endometrial carcinoma (EC), and ovarian carcinoma (OC), which are related to hormonal dysfunction, especially estrogen dysfunction. 61 In the last few years, the incidence of these malignant diseases has increased and is still not restrained sufficiently. The study of the regulation of physiological function or effects of hormones, especially in endocrine therapy that requires super selective intervention hormone receptor subtypes as the main means of hormone-dependent/related tumor, has become a new research hotspot in translational medicine. [62] [63] [64] Using selective estrogen receptor (ER) antagonist (selective ER modulators, SERMs) targeting the ER in treating tumors in patients has produced varying clinical effects. For instance, ideal biotherapeutic effects can be achieved in breast cancer, whereas these agents have both anticancer and carcinogenic effects in endometrial carcinoma. Furthermore, the effect of endocrine therapy in ovarian cancer is unclear. 65, 66 Obviously, these phenomena cannot be reasonably explained by the classical estrogen-ER signaling pathway theory.
Because of the known structural homology between ERRα and ERα as well as the crucial role of ERα in breast tumors, studies have mainly concentrated on the latent association with the traditional ERα in the early years. Initially, it was a surprising finding that ERRα binds DNA segments harboring the estrogen-response element (ERE) in vitro. [67] [68] [69] After that, in different endocrine-related cancers, the potential of ERRα as a biomarker has been gradually proved. 2 Compared to the expression in normal tissues, ERRα expression was elevated in tumor samples from patients with ovarian cancer. 16 In ovarian, endometrial and colorectal cancers, ERRα expression increases with advancing clinical stages, so we concluded there is a strong positive correlation between ERRα and tumor aggressiveness. 16, 70, 71 In breast cancer, ERRα expression has also been associated with unfavorable clinical outcomes. 72 Further, in an animal model of brain metastasis, it was observed that the mRNA expression of ERRα increased. 73 Our previous study showed that ERRα was correlated with the development of ovarian cancer, which could be used as a marker for poor prognosis and it may be associated with decreased patient survival. 17 Similar observations have also been made in endometrial tumors.
With the continuous exploration of tumor development mechanisms, in 2011, American scientists Douglas Hanahan and Robert A Weinberg 74 identified six additional characteristics of tumor cells increasing the existing number to 10: self-sufficiency in growth signals, resistance to cell death, unlimited replicative ability, insensitivity to growth inhibitory signals, sustained angiogenesis, evasion of immune surveillance, tissue invasion and transfer, promotion of tumor inflammation, genomic instability and mutation, and abnormal cell energy. 
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ERRα regulates cellular metabolism in gynecological endocrine-related cancer energy, especially for producing enough nucleic acids, lipid, and protein for each cell, which must undergo accelerated metabolism and biosynthesis. 27 The changes of cellular metabolism in cancer cells include enhanced glycolysis and oxidation phosphorylation, glutamine uptake, increased glutamine levels, FAO and lipid biosynthesis level changes, and increased pentose phosphate metabolism. Thus, the establishment of ERRα as a master regulator of cellular metabolism has generated renewed interest in investigating the coordination of ERRα-driven metabolism in endocrine-related gynecological cancers.
Advances in eRRα antagonist development
Considering the role of ERRα in cell metabolism, many researchers have attempted to identify molecules with agonist activity for the treatment of metabolic diseases such as breast cancer and diabetes. However, compounds with significant ERRα agonist activity have not been identified in recent years. Some antagonist/inverse agonists have been found to inhibit ERRα activity in vitro or in vivo. Although these compounds have not been used clinically, they play a key role in exploring the biological role of ERRα and the pathways involved. The first selective ERRα antagonist, XCT790, can bind ERRα and blocking its interaction with coactivators, downregulating the expression of target genes for ERRɑ, and inhibiting cell proliferation in vitro. 35, 75, 76 Compound A ([N-[(2Z)-3-(4, 5-dihydro-1, 3-thiazol-2-yl)-1, 3-thiazolidin-2-ylidene]-5Hdibenzo[a,d] [7] annulen-5-amine], an ERRα selective antagonist, exhibits growth inhibition of ER-positive and ER-negative breast tumor both in vitro and in vivo. 36 A diaryl ether-based thiazolidinedione (compound 29) for the treatment of metabolic disease, 77 as well as a selective ERRα antagonist, has good pharmacokinetic properties, but is only effective in animal models of insulin resistance and obesity, its role in breast cancer has not been confirmed.
Zhang et al reported that HSP1604 (methyl-N-(4-(((4-butoxy-N- (4- ((N-(4-methylbenzyl) ,methylsulfonamido) methyl)phenyl)phenyl)sulfonamido)methyl)phenyl)-N-(methylsulfonyl)glycinate) was the strongest inhibitor of the constitutive transcriptional activity of ERRα. It directly binds to the ERRα to decrease its expression and downstream target genes. In vitro, HSP1604 also inhibited the proliferation of multiple cancer cells lines and the migration of breast cancer cells. 78 These compounds are extremely valuable for the discovery of new drugs, making ERRα an alternative strategy for treating endocrine-related gynecological tumors and other related diseases.
Conclusion and perspectives
The findings summarized in this review support the key function of ERRα in coordinating metabolic programs, which subsequently promote tumor cell growth, division, proliferation, angiogenesis, migration, metastasis, and drug resistance. Although the effectiveness of some ERRα antagonists have been validated in animal studies, they have not been reported in clinical trials. However, as a major regulator of the energy metabolism process, changes in the activity of ERRα would be a valuable strategy for the development of therapies targeting cancer metabolism. Recent research studies show the causal role of ERRα in cancer pathogenesis. With the enhanced understanding of the receptor as a drug target, it is believed that the information highlighted in this review will encourage the development of new therapeutic strategies that are urgently needed to treat endocrine-related gynecologic cancers.
